The FDA assessed the protection and success of atidarsagene autotemcel according to info from 37 small children who received atidarsagene autotemcel in two single-arm, open-label clinical trials As well as in an expanded accessibility program.[seven] Youngsters who gained treatment method with atidarsagene autotemcel were compared to untreated youngsters (pure historical https://andresradef.blogs-service.com/66633718/a-review-of-libmeldy